Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study.

BACKGROUND Inappropriate prescribing increases patient illness and death owing to adverse drug events. The inclusion of genetic information into primary care medication practices is one solution. Our aim was to assess the ability to obtain and genotype saliva samples and to determine the levels of use of a decision support tool that creates medication options adjusted for patient characteristics, drug-drug interactions and pharmacogenetics. METHODS We conducted a cohort study in 6 primary care settings (5 family practices and 1 pharmacy), enrolling 191 adults with at least 1 of 10 common diseases. Saliva samples were obtained in the physician's office or pharmacy and sent to our laboratory, where DNA was extracted and genotyped and reports were generated. The reports were sent directly to the family physician/pharmacist and linked to an evidence-based prescribing decision support system. The primary outcome was ability to obtain and genotype samples. The secondary outcomes were yield and purity of DNA samples, ability to link results to decision support software and use of the decision support software. RESULTS Genotyping resulted in linking of 189 patients (99%) with pharmacogenetic reports to the decision support program. A total of 96.8% of samples had at least 1 actionable genotype for medications included in the decision support system. The medication support system was used by the physicians and pharmacists 236 times over 3 months. INTERPRETATION Physicians and pharmacists can collect saliva samples of sufficient quantity and quality for DNA extraction, purification and genotyping. A clinical decision support system with integrated data from pharmacogenetic tests may enable personalized prescribing within primary care. Trial registration: ClinicalTrials.gov, NCT02383290.

[1]  Evangelos Kontopantelis,et al.  Examining variations in prescribing safety in UK general practice: cross sectional study using the Clinical Practice Research Datalink , 2015, BMJ : British Medical Journal.

[2]  G. Ginsburg,et al.  Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. , 2014, Pharmacogenomics.

[3]  P. Canonico,et al.  Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. , 2014, Pharmacogenomics.

[4]  Roger B. Davis,et al.  Physicians' decisions to override computerized drug alerts in primary care. , 2003, Archives of internal medicine.

[5]  W. Assendelft,et al.  Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19 , 2011, European Journal of Clinical Pharmacology.

[6]  Alessandra Marengoni,et al.  Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity , 2015, BMJ : British Medical Journal.

[7]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[8]  J. Saldivar,et al.  Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility , 2016, Pharmacogenomics and personalized medicine.

[9]  R. Altman,et al.  Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. , 2015, Mayo Clinic proceedings.

[10]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[11]  Joshua Borus,et al.  Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.

[12]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[13]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[14]  S. Haga,et al.  Comparison of delivery strategies for pharmacogenetic testing services , 2014, Pharmacogenetics and genomics.

[15]  D. Brixner,et al.  The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy , 2016, Journal of medical economics.

[16]  Deirdre Hennessy,et al.  Prescription medication use by Canadians aged 6 to 79. , 2014, Health reports.

[17]  D. Ashcroft,et al.  Prevalence of Adverse Drug Events in Ambulatory Care: A Systematic Review , 2011, The Annals of pharmacotherapy.

[18]  Marc Berg,et al.  Overriding of drug safety alerts in computerized physician order entry. , 2006, Journal of the American Medical Informatics Association : JAMIA.

[19]  T. Mamiya,et al.  How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. , 2014, Pharmacogenomics.

[20]  Ira J. Kalet,et al.  Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support , 2010, BMC Bioinformatics.

[21]  Emily S. Patterson,et al.  Comparing the Effectiveness of Alerts and Dynamically Annotated Visualizations (DAVs) in Improving Clinical Decision Making , 2015, Hum. Factors.

[22]  H. Britt,et al.  BEACH program update. , 2015, Australian family physician.

[23]  Thomas H. Payne,et al.  Review Paper: Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review , 2007, J. Am. Medical Informatics Assoc..

[24]  B. Franklin,et al.  The causes of prescribing errors in English general practices: a qualitative study. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

[25]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[26]  A. Melander,et al.  Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care , 2007, The Annals of pharmacotherapy.

[27]  W. Ungar,et al.  The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. , 2015, Genome.

[28]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[29]  T. Skaar,et al.  Implementation of a pharmacogenomics consult service to support the INGENIOUS trial , 2016, Clinical pharmacology and therapeutics.

[30]  D. Bates,et al.  Ambulatory Computerized Prescribing and Preventable Adverse Drug Events , 2016, Journal of patient safety.

[31]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[32]  C. Teljeur,et al.  Prescriber variation in potentially inappropriate prescribing in older populations in Ireland , 2014, BMC Family Practice.

[33]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.